Hosted on MSN1d
Trust chosen for national genetic testing pilot
DONCASTER and Bassetlaw Teaching Hospitals has been named as one of just four NHS sites in England selected to test a new ...
openheart.bmj3d
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...
Medscape4d
Better Outcomes With Antithrombotics: Here’s How PPIs Help
Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...
Doncaster and Bassetlaw Teaching Hospitals chosen for trailblazing national genetic testing pilot
Doncaster and Bassetlaw Teaching Hospitals (DBTH) has been named as one of just four NHS sites in England selected to test a ...
ahajournals.org16d
Abstract WP289: Cytochrome P450 2C19 genotypes and the efficacy of clopidogrel in non-diabetic patients with ischemic stroke
Background: The ABCD-GENE score, incorporating age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genotypes, is a validated risk score that ...
ahajournals.org16d
Abstract TP228: CYP2C19 GENETIC VARIANTS AND THROMBOTIC RISK IN CLOPIDOGREL THERAPY: A PATH TO PERSONALIZED ANTI-PLATELET THERAPY
Clopidogrel, an antiplatelet prodrug, requires activation by CYP enzymes to inhibit platelet activation. Clopidogrel resistance, affecting 4-30% of patients, is often due to CYP2C19 gene variations, ...